Drug
DS 1040b
DS 1040b: highest development phase Phase 1/2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS-1040b NCT02923115 | Phase 1/2 | Pulmonary Embolism |
Latest
No recent events.
Follow DS 1040b on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.